
Your Feed
Update on KRdB Clinical Trial at Levine Cancer Institute | Shebli Atrash, MD | IMS 2023
Malignancies after Tandem ASCT for those on Total Therapy Protocols | Samer Al’Hadidi, MD | IMS 2023
Trends in 11;14 FISH Testing for Myeloma | Linda Baughn, PH.D. | IMS 2023
Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023
Update on Risk Stratification in MGUS and SMM | Doctors Callander and Beksac | IMS 2023
Wearable Tech for Early Detection of CRS in CAR T-cell Therapy | Sridevi Rajeeve, MD | IMS 2023
Immune Based Strategies to Improve Outcomes of Cellular Therapies | Rakesh Popat, PhD | IMS 2023
Optimizing Imaging in Multiple Myeloma | Jens Hillengass, MD | IMS 2023
Managing Acute Immune Complications | Krina Patel, MD | IMS 2023
Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023






